Please Login to participate

Course HomeCourse Progress
  • Pre-Test
  • Access Webcast
  • Download PDF of Slides
  • Evaluation
  • Certificate

Management Strategies for Multiple Myeloma: Emerging Agents, Optimal Sequencing, and Ongoing Challenges

FACULTY

Natalie Callander, MD
Associate Professor of Medicine
University of Wisconsin Carbone Cancer Center

Ajay Chari, MD
Associae Professor of Medicine
Icahn School of Medicine at Mount Sinai

Hira Mian MD
Assistant Professor of Oncology
McMaster University
 

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute, City of Hope Cancer Center

Saad Z. Usmani, MD, MBA, FACP
CHief of Myeloma Service
Memorial Sloan Kettering Cancer Center

Cindy Varga, MD
Associate Professor
Levine Cancer Institute

Andrew J. Yee, MD
Clinical Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center

 

PROVIDER STATEMENT

Provided by HMP Education, an HMP Global Company.

For questions regarding this educational activity, or to cancel your account, please call 609-371-1137 or email accreditation@hmpglobal.com.

INTENDED LEARNERS

This activity is designed to meet the educational needs of U.S. hematologists, medical oncologists, and other health-care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc) who are involved and/or interested in the treatment of patients with multiple myeloma, lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.

LEARNING OBJECTIVES

After participating in this activity, learners should be better able to:

  • Define the frontline strategy for MM treatment
  • Evaluate clinical efficacy and safety data of newer and emerging MM therapies and considerations for their combination and sequencing
  • Identify R/R MM management strategies, incorporating novel therapeutic targets to overcome the challenges of tolerability, AEs, and managing comorbidities

ACTIVITY OVERVIEW

This on-demand webcast is available with synchronized slides and audio.

To be eligible for credit, participants must complete the educational activity, complete the X-question post-test with a score of 70% or better, and complete the evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: August 23, 2022 
Expiration Date: August 22, 2023 
Estimated Time to Complete: 2.0 hour

There is no fee associated with this activity.

HARDWARE/SOFTWARE REQUIREMENTS

The evaluation is accessible after the activity via a PC or Mac computer with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. 

CONTINUING EDUCATION

In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

HMP Education designates this internet enduring activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACISTS

This internet enduring, knowledge-based activity (Universal Activity Number: JA0006201-0000-22-134-H01-P) has been approved for a maximum of 2.0 contact hour (.2 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. HMP Education is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

NURSES

This continuing nursing education internet enduring activity awards 2.00 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 2.00 contact hour. 

NURSE PRACTITIONERS

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.

PHYSICIAN ASSISTANTS

HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet live/enduring activity is designated for 2.00 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.

 

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of HMP Education.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither HMP Education nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Education or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

  1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
  2. Any investigational, off-label, or non-FDA approved content or discussion

HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:

  1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
  2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
  3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

FACULTY

The faculty has reported the following:

Natalie Callander: has no relevant disclosures.

Ajai Chari, MD: Advisory Board, Consultant, Grant/Research Support - Amgen; Consultant - Antengene; Consultant - Bristol Myers Squibb; Advisory Board, Consultant, Grant/Research Support - Celgene; Grant/Research Support - GSK; Advisory Board, Consultant, Grant/Research Support - Janssen; Advisory Board, Consultant - Karyopharm; Grant/Research Support - Novartis Pharmaceuticals; Grant/Research Support - Oncopeptides; Grant/Research Support - Pharmacyclics; Advisory Board - Sanofi; Advisory Board, Grant/Research Support - Seattle Genetics; Advisory Board, Consultant, Grant/Research Support - Takeda

Hira Mian, MD: Advisory Board - Amgen; Advisory Board - Bristol Myers Squibb; Advisory Board, Grant/Research Support - Janssen; Advisory Board - Takeda

Joseph R. Mikhael, MD, MEd, FRCPC, FACP: Consultant - Amgen; Consultant - Bristol Myers Squibb; Consultant - Janssen; Consultant - Karyopharm; Consultant - Oncopeptides; Consultant - Sanofi; Consultant - Takeda

Saad Usmani, MD, MBA, FACP: has no relevant disclosures.

Cindy Varga, MD: has no relevant disclosures.

Andrew Yee, MD: Advisory Board - Adaptive; Advisory Board, Grant/Research Support - Amgen; Advisory Board, Grant/Research Support - Bristol Myers Squibb; Advisory Board, Grant/Research Support - Celgene; Advisory Board - GSK; Advisory Board, Grant/Research Support - Janssen; Advisory Board, Consultant - Karyopharm; Advisory Board - Oncopeptides; Consultant - Regeneron; Advisory Board - Sanofi; Advisory Board, Grant/Research Support - Takeda

 

PLANNING COMMITTEE

Susie Seaman, NP, MSN, CWCN, CWS (nurse planner)
Wound Clinic, Family Health Centers of San Diego
San Diego, California

Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).

HMP Education planners and staff include Samantha Conforti, Kelly Jackson, Amrita Kabi, Randy Robbin, and Andrea Zimmerman.

No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).

ADA STATEMENT

HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

PRIVACY POLICY

HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2022 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.

GRIEVANCE POLICY

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Conforti, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@hmpglobal.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint.

COMMERCIAL SUPPORT

Supported by an independent educational grant from Karyopharm Therapeutics .